Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 14
Submit an article Journal homepage
164
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1

Rossana Berardi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
, MD,
Elena Maccaroni Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Azzurra Onofri Università Politecnica delle Marche, Postgraduate School of Oncology, Via Conca 71, 60126 Ancona, Italy
,
Riccardo Giampieri Università Politecnica delle Marche, Postgraduate School of Oncology, Via Conca 71, 60126 Ancona, Italy
,
Alessandro Bittoni Università Politecnica delle Marche, Postgraduate School of Oncology, Via Conca 71, 60126 Ancona, Italy
,
Mirco Pistelli Università Politecnica delle Marche, Postgraduate School of Oncology, Via Conca 71, 60126 Ancona, Italy
,
Mario Scartozzi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Chiara Pierantoni Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Maristella Bianconi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
&
Stefano Cascinu Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
 show all
Pages 2245-2258 | Published online: 29 Jul 2009

Bibliography

  • Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
  • Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the county of Stockholm. Lancet 2000;356:93-6
  • Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15
  • NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50
  • Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative radiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40
  • Minsky BD. Adjuvant therapy for rectal cancer. ASCO Annual Meeting Educational Book. J Clin Oncol 2002;20:472-7
  • Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999;42:167-73
  • Madoff RD. Chemoradiotherapy for rectal cancer – when, why, and how? N Engl J Med 2004;351:1790-2
  • Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992;10:79-84
  • Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 2000;46:323-7
  • Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005;23:1847-58
  • Pollack J, Holm T, Cedermark B, et al. Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 2006;49:345-52
  • Hendren SK, Swallow CJ, Smith A, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212-23
  • Heriot AG, Tekkis PP, Fazio VW, et al. Adjuvant radiotherapy is associated with increased sexual dysfunction in male patients undergoing resection for rectal cancer: a predictive model. Ann Surg 2005;242:502-10
  • Kim NK, Aahn TW, Park JK, et al. Assessment of sexual and voiding function after total mesorectal excision with pelvic autonomic nerve preservation in males with rectal cancer. Dis Colon Rectum 2002;45:1178-85
  • Palmer G, Martling A, Lagergren P, et al. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol 2008;15:3109-17
  • Wilson TR, Alexander DJ. Clinical and non-clinical factors influencing postoperative health-related quality of life in patients with colorectal cancer. Br J Surg 2008;95:1408-15
  • Swedish Rectal Cancer Trial. Local recurrence rate in a randomized multicentre trial of preoperative radiotherapy compared to surgery alone in resectable rectal carcinoma. Eur J Surg 1996;162:397-402
  • Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. JAMA 2000;248:1008-15
  • Kapiteijn E, Kranenbarg EK, Steup WH, et al. Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prespective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg 1999;165:410-20
  • Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811-20
  • Weinstein GD, Rich TA, Shumate CR, et al. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:197-204
  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15-24
  • Bosset JF, Calais G, Daban A. Does the addition of chemotherapy to radiation increase acute toxicity in patients with rectal cancer: Report of 22921 EORTC phase III trial. J Clin Oncol 2003;21:294(abstr 1179)
  • Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5
  • Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001;49:987-95
  • Rullier E, Goffre B, Bonell C. Preoperative radio-chemotherapy and sphincter saving resection in T3 carcinomas of the lower third of the rectum. Am Surg 2001;234:633-40
  • Ruo L, Tikoo S, Klimstra D. Long term prognostic significance of extended rectal cancer response to preoperative radiation and chemotherapy. Am Surg 2002;236:75-81
  • Roh M, Petrelli N, Wieand H. Phase III randomised trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). J Clin Oncol 2001;20(1):123(abstr 490)
  • Rouanet P, Rivoire M, Lelong B, et al. Sphincter preserving surgery after preoperative treatment for ultra-low rectal carcinoma. A French multicenter prospective trial: GERRCAR 1. J Clin Oncol 2006;24(18):152(abstr 3527)
  • Bujko K, Kepka L, Michalski W, et al. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006;80:4-12
  • Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211:187-95
  • Sauer R. Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer: first results of the German rectal cancer study (CAO/ARO/AIO-94). Int J Radiat Oncol Biol Phys 2003;57:124-5
  • Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396-402
  • Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003;46:448-53
  • Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 1999;45:1175-84
  • Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004;22:2214-32
  • Byfield JE, Calabro-Jones P, Klisak I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracilor ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33
  • Hartley A, Ho KF, McConkey C, et al. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005;78:934-8
  • Schiessel R, Karner-Hanusch J, Herbst F, et al. Intersphincteric resection for low rectal tumours. Br J Surg 1994;81:1376-8
  • Chamlou R, Parc Y, Simon T, et al. Long-term results of intersphincteric resection for low rectal cancer. Ann Surg 2007;246:916-21; discussion 921-2
  • Weiser MR, Quah HM, Shia J, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg 2009;249:236-42
  • Steele GD Jr, Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999;6:433-41
  • Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701
  • Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-96
  • Glimelius B. Chemoradiotherapy for rectal cancer – is there an optimal combination? Ann Oncol 2001;12:1039-45
  • Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96
  • Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007;25:4379-86
  • Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002;20:3983-91
  • Gerard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003;21:1119-24
  • Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group trial 0012. J Clin Oncol 2006;24:650-5
  • Aschele C, Pinto C, Rosati G, et al. Pre-operative FU-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Preliminary safety findings of the STAR (Studio Terapia Adiuvante Retto)-01 randomized trial. Proceedings of the 2007 Gastrointestinal Cancers Symposium of ASCO Orlando FL, 19-21 Jan 2007: abstract 233
  • Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer [abstract 4021]. J Clin Oncol 2008;26(15S):183s
  • Williams K, Telfer B, Stratford I, et al. ZD1839, a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancers xenograft model. Br J Cancer 2002;86:1157-61
  • Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006;24:656-62
  • Machiels JP, Sempoux C, Scalliet P, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007;18:738-44
  • Willett CG, Kozin SV, Duda DG, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006;33(5 Suppl 10):S35-S40
  • Czito BG, Bendell JC, Willett CG, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007;68:472-8
  • Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 2006;66:1378-83
  • Rodel C, Arnold D, Hipp M, et al. Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1081-6
  • Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract 2]. J Clin Oncol 2008;26(Suppl):5s
  • Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006;47:1241-8
  • Available from: http://www.cancer.gov/clinicaltrials/search [Last accessed 20 July 2009]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.